NCT05005299 - Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 8, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Leukemia, Myeloid, AcuteLeukemia, Lymphoblastic, Acute, L1Leukemia, Lymphoblastic, Acute, L2Myelodysplastic SyndromesNon-hodgkin LymphomaPlasma Cell Myeloma

Interventions

DRUG

Venetoclax

Venetoclax is administered as an oral tablet once daily.

DRUG

Fludarabine

Fludarabine is administered as an intravenous infusion at a dose of 30mg/m2 daily, to be administered over 30 minutes.

DRUG

Cyclophosphamide

Cyclophosphamide is administered as an intravenous infusion at a dose of 750mg/m2 daily, to be administered over 30 minutes and to commence 1 hour after fludarabine infusion.

Trial Locations (1)

3050

RECRUITING

Melbourne Health, Melbourne